Stockscreener 앱 받기
21.13
0.84%
-0.18
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
Why Sarepta Therapeutics (SRPT) Is Down 11.3% After Elevidys Safety Setback And Revenue MissAnd What's Next - Yahoo Finance
Has Sarepta Therapeutics (SRPT) Fallen Too Far After 82% One-Year Share Price Drop? - Yahoo Finance
Sarepta Preliminary Results: Not What The Market Wanted To Hear (NASDAQ:SRPT) - Seeking Alpha
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - The Globe and Mail
Sarepta Therapeutics: Is Elevidys A Bust? (NASDAQ:SRPT) - Seeking Alpha
Is Sarepta Therapeutics Inc stock trending bullishJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - baoquankhu1.vn
Sentiment Recap: Can Ramaco Resources Inc withstand a market correctionJuly 2025 Opening Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz
Sarepta Therapeutics' (SRPT) "Sell" Rating Reiterated at HC Wainwright - MarketBeat
Sarepta shares cut to $0 at H.C. Wainwright - MSN
H.C. Wainwright reiterates Sell rating on Sarepta Therapeutics stock By Investing.com - Investing.com Canada
SRPT: Today's Analyst Ratings and Price Target Update | SRPT Sto - GuruFocus
Forecasting The Future: 8 Analyst Projections For Sarepta Therapeutics - Benzinga
Mizuho reiterates Outperform rating on Sarepta stock, maintains $26 target By Investing.com - Investing.com UK
Analysts Have Conflicting Sentiments on These Healthcare Companies: Establishment Labs Holdings (ESTA), Sarepta Therapeutics (SRPT) and Insmed (INSM) - The Globe and Mail
Analyst Downgrade: Is Sarepta Therapeutics Inc stock heavily shorted2025 Key Lessons & High Accuracy Trade Signal Alerts - baoquankhu1.vn
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026 - BioSpace
Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 6.7%What's Next? - MarketBeat
Sarepta falls after gene therapy Elevidys misses estimates - The Boston Globe
SRPT: Entering 2026 with strong finances, new data, and major pipeline and regulatory milestones ahead - TradingView — Track All Markets
SRPT Sees Potential Turnaround Despite Soft Q4 Sales - GuruFocus
SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns - Stocktwits
Sarepta reconfirms yearly sales floor for Elevidys of $500.0 mln - marketscreener.com
SRPT: Entering 2026 with strong financials, expanded therapy reach, and key clinical milestones ahead - TradingView — Track All Markets
Sarepta Falls After Gene Therapy Elevidys Misses Estimates - Bloomberg.com
Sarepta (SRPT) Reports Strong 2025 Revenue Growth and Financial Position - GuruFocus
Sarepta Therapeutics (SRPT) Reports Lower Than Expected Revenue for 2025 - GuruFocus
Sarepta (SRPT) Shares Decline Following Q4 Revenue Announcement - GuruFocus
Sarepta Preliminary Q4, 2025 Net Product Revenue Miss Estimates; Shares Fall - marketscreener.com
Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? - Benzinga
Sarepta Therapeutics Q4 prelim net product revenue misses estimates - TradingView — Track All Markets
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues - The AI Journal
Sarepta reports $1.86 billion in 2025 product revenue - StreetInsider
Market Outlook: What is Sarepta Therapeutics Incs market positionJuly 2025 Gainers & Smart Swing Trading Alerts - baoquankhu1.vn
Sarepta Therapeutics (SRPT) Stock Analysis: Navigating Through Challenges Amidst a Promising Biotech Future - DirectorsTalk Interviews
Sarepta (SRPT) Soars 15% on Bullish Rating - MSN
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Aug Breakouts: Why Coloured Ties Capital Inc 97A0 stock could break out in 2025Quarterly Trade Review & Daily Volume Surge Signals - moha.gov.vn
Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy - MSN
Signal Recap: Is Sarepta Therapeutics Inc stock resilient to inflationJuly 2025 PostEarnings & AI Enhanced Trading Alerts - moha.gov.vn
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Is Sarepta Therapeutics Inc. stock resilient to inflationQuarterly Profit Summary & Daily Technical Stock Forecast Reports - ulpravda.ru
Can Sarepta Therapeutics Inc. (AB3A) stock ride next bull market cycleBear Alert & Safe Entry Momentum Stock Tips - ulpravda.ru
Why (SRPT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Sarepta Therapeutics seeks clinical trial clearance for SRP-1005 - BioWorld MedTech
Europe Gene Therapy Market to hit US$ 8,780.77 Million by 2033 | - openPR.com
Leerink Partners maintains Market Perform rating on Sarepta stock ahead of 2026 data - Investing.com UK
Assessing Sarepta Therapeutics (SRPT) Valuation After SRP-1005 Huntington’s Disease Trial Application - Yahoo Finance
Will Sarepta Therapeutics Inc. (AB3A) stock issue positive guidanceRisk Mitigation Techniques & Free Dynamic Capital Growth - ulpravda.ru
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigat - pharmiweb.com
Sarepta Therapeutics announces submission of clinical trial application for SRP-1005 - marketscreener.com
Sarepta submits clinical trial application for Huntington’s disease drug By Investing.com - Investing.com India
Sarepta submits clinical trial application for Huntington’s disease drug - Investing.com
Sarepta (SRPT) Moves Forward with New Clinical Trial Application for Huntington's Treatment - GuruFocus
Sarepta submits clinical trial application for Huntington's disease drug - StreetInsider
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease - Business Wire
Top 10 muscular dystrophy news stories of 2025 - Muscular Dystrophy News
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stock2026 world cup usa national team round of 32 star players high defensive line expert forecast preview - Улправда
Sarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan - MSN
Standing by Our Decision: How EXONDYS 51 Became Part of Our Treatment Plan - Muscular Dystrophy News
Buybacks Report: What risks investors should watch in Sarepta Therapeutics Inc stockBreakout Watch & Intraday High Probability Setup Alerts - moha.gov.vn
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - New Castle News
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Biotech Pioneer with a Mixed Valuation Outlook - DirectorsTalk Interviews
Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Cwm LLC - MarketBeat
United States Neuromuscular Disease Therapeutics Market - openPR.com
4.73%
0.92%
자본화:
|
볼륨(24시간):